XRCC4

Across TCGA pan-cancer cohorts, XRCC4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated XRCC4 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher XRCC4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated XRCC4 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where XRCC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.559	0.277	.023	9	view →
CCRCC	OS	Quartile	All	0.597	1.000	.016	6	view →
PDAC	OS	Quartile	III,IV	0.620	0.225	.014	6	view →
HNSC	DFS	Median	III,IV	0.916	0.985	.035	2	view →
LUAD	DFS	Tertile	All	0.502	0.915	.025	2	view →
LSCC	OS	Quartile	All	0.773	0.960	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

XRCC4–GBM (OS)

Open the GBM breakdown →